Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine.

Leyens L1, Richer Ai??, Melien A?, Ballensiefen W, Brand A. Abstract Scientific knowledge and our understanding of the human body and diseases have limited any possible treatment tailoring to each patient. The technological advances enabling the integration of various data sets (e.g. ‘-omics’, microbiome, epigenetics and environmental exposure) have facilitated a greater understanding of the(…)